PeptideLabs Logo
PeptideLabs
All profiles

Semax

Peptide · Neuroscience

Is studied experimentally for neuronal protection and plasticity signalling; it lacks FDA/EMA approval.

Not FDA/EMA approved
LibraryNo account · this device only

Also known as: XA · ACTH(4-7) analogue

Use at a glance

Semax

Is studied experimentally for neuronal protection and plasticity signalling; it lacks FDA/EMA approval.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Study information · not a personal use plan

What amount?
0.6–1.5 mg / 24 h
How often?
Frequency not stated here; see the study plan
What time of day?
morning, before 2 pm per source
In what setting?
Intranasal research
How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
Overview of all entries

  • Semax · Intranasal research

    Study information · not a personal use plan

    0.6–1.5 mg / 24 h · Frequency not stated here; see the study plan · morning, before 2 pm per source

  • Semax · Community subcutaneous reports

    Online report · not medically verified

    <1 mg / administration · not reliably established · not reliably established

  • Semax · cycle / pause

    Online report · not medically verified

    — · 4–6 weeks / 2–4 weeks · not reliably established

More factsPeptide · Neuroscience
Classification
Peptide · Neuroscience
Research focus
Is studied experimentally for neuronal protection and plasticity signalling; it lacks FDA/EMA approval.
Evidence
Preclinical
Status
Not FDA/EMA approved

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Schedule explained in detailCommunity/research information only

Amount status

For subcutaneous use, the community source only cites 'under 1 mg per dose', without a dependable standard. Intranasal 0.6–1.5 mg per day is described in the context of Russian studies/pharmacology.

Profile evidence level: preclinical.

Timing

Intranasal in the morning/early afternoon; community subcutaneous timing is not validated.

No individual recommendation.

Cycle/duration

Community cycles of 4–6 weeks with a 2–4 week break. No internationally confirmed therapy.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

Simple syringe and pen calculator

Choose your device and enter your known values. One result appears below.

You know the total solution volume. Calculate the scale mark for your entered amount.

Which syringe or pen?
More syringes
How much substance is in the vial?

Total amount on the label—not the container size in ml.

What is the total solution volume?

This is the total solution after dissolving, not automatically the water to add. Follow the specific product's instructions for preparation.

Which known amount do you want to convert?

Your known input. The calculator does not choose a suitable amount.

Complete the three number fields to see a result.

The calculator chooses neither a dose nor a mixing liquid. It does not check sterility, stability or suitability for use.

What the units mean
  • mg / µg = substance amount. 1 mg = 1,000 µg.
  • ml = liquid volume, not substance amount.
  • U / clicks = device markings. Their meaning depends on the device scale.
Calculation and extra figures

Complete the three number fields to see a result.

Scale and precision notes

Arithmetic does not establish measurement accuracy. Displayed numbers may be rounded; very small numbers use scientific notation. Intermediate values may not be readable on your device. Do not round fractional clicks up or down.

U-100 is used as a volume scale: 100 U = 1 ml. It is not the substance amount.

Copy this value from your pen's instructions. A 3 ml cartridge does not tell you the volume delivered at 60 clicks.

Source for the U-100 scale
Formulas and individual stepsOpen only if you want the deeper explanation.

Formulas used

  • Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
  • Volume (ml) = target µg ÷ concentration
  • U-100 units = volume ml × 100

Mixing process described by the reference

01

Verify inputs

Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.

02

Disinfect stoppers

The reference calls for separate alcohol swabs and sterile single-use materials.

03

Add fluid slowly

The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.

04

Dissolve gently

The vial is rolled or swirled gently, not shaken, until no visible solids remain.

05

Inspect visually

Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.

06

Label and store by product data

Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.

An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

20 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount500 µg
Concentration10,000 µg/ml
U-1005 U
Volume0.05 ml

20 mg · assumed final volume: 4 ml

Community calculation example
Calculated amount500 µg
Concentration5,000 µg/ml
U-10010 U
Volume0.1 ml
All preparation informationProduct details and calculation examples from the available sources.

Community arithmetic: 20 mg +2 ml →0.5 mg =5 U; 20 mg +4 ml →0.5 mg =10 U. Not a recommendation and not transferable to nasal products.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Synthetic ACTH-derived peptide

Semax is classified as “Synthetic ACTH-derived peptide”. Is studied experimentally for neuronal protection and plasticity signalling; it lacks FDA/EMA approval. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Neuroprotective signalling

This examines whether a substance can protect nerve cells from stress or damage, such as after oxygen deprivation in a cell model. Cell survival and signalling markers in nerve tissue under lab conditions are measured.

02

Neuroendocrine signalling

This examines how the nervous system and hormone-producing glands communicate with each other, similar to a two-way phone line connecting the brain to distant organs. Researchers typically measure hormone levels in blood alongside markers of nervous system activity.

03

Anxiolytic signalling

This studies how a peptide affects stress and anxiety responses in animal models, similar to observing whether an animal stays calmer in an unfamiliar environment. Behavioural tests and stress hormone levels are measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Nootropic forums

Subjective effects on concentration, mood, or stress perception after taking experimental neuropeptides are discussed, often based on personal journals. Such self-reported impressions are strongly influenced by expectation and do not replace controlled studies.

Biohacker and longevity forums

Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Central nervous system effects may include fatigue, agitation, headache, dizziness, sleep or mood changes. Interactions and long-term neuropsychiatric safety are unclear for unapproved substances.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, epilepsy, severe psychiatric or neurological disease, and sedating or stimulating concomitant medicines require medical review.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Studies may track cognition, sleep, mood, vital signs and adverse events depending on the endpoint; daily subjective impressions do not replace standardised measurement.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

It lacks FDA/EMA approval; evidence is mostly from experimental models.

Clinical evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

Semax is ACTH-derived and linked more to neuronal plasticity, while Selank derives from tuftsin and is more associated with anxiety and stress signalling.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile